AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

OTCMKTS:RHHBYRoche Holdings AG Basel Stock Price, Forecast & News

$43.43
+0.08 (+0.18 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$43.30
Now: $43.43
$43.54
50-Day Range
$39.39
MA: $43.66
$45.61
52-Week Range
$32.95
Now: $43.43
$46.00
Volume948,695 shs
Average Volume2.51 million shs
Market Capitalization$297.43 billion
P/E Ratio17.10
Dividend Yield1.66%
Beta0.4
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases. The company's diagnostic solutions include blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol and coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis, heterogeneous immunochemistry, homogeneous immuno assay, immunology, and infectious disease solutions; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control services; real-time PCR diagnostic systems; urinalysis; and serum work area and workflow solutions. In addition, it offers gene expression, gene sequencing, and real time PCR systems for researchers. The company licenses its products or technologies to third parties. Roche Holding AG has a collaboration agreement with San Francisco-based Syapse to develop software that integrates fragmented clinical, molecular, and data on treatment plans and health outcomes. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Read More
Roche Holdings AG Basel logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RHHBY
CUSIPN/A
CIKN/A
Phone41-61-688-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$61.87 billion
Cash Flow$3.20 per share
Book Value$5.27 per share

Profitability

Miscellaneous

Employees97,735
Outstanding Shares6,848,488,000
Market Cap$297.43 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Roche Holdings AG Basel (OTCMKTS:RHHBY) Frequently Asked Questions

How has Roche Holdings AG Basel's stock been impacted by COVID-19 (Coronavirus)?

Roche Holdings AG Basel's stock was trading at $40.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RHHBY shares have increased by 6.2% and is now trading at $43.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Roche Holdings AG Basel?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche Holdings AG Basel in the last year. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Roche Holdings AG Basel.

What price target have analysts set for RHHBY?

12 brokerages have issued twelve-month price objectives for Roche Holdings AG Basel's shares. Their forecasts range from $48.00 to $48.00. On average, they anticipate Roche Holdings AG Basel's share price to reach $48.00 in the next year. This suggests a possible upside of 10.5% from the stock's current price. View analysts' price targets for Roche Holdings AG Basel.

Has Roche Holdings AG Basel been receiving favorable news coverage?

News stories about RHHBY stock have trended somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Roche Holdings AG Basel earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRoche Holdings AG Basel.

Who are some of Roche Holdings AG Basel's key competitors?

Who are Roche Holdings AG Basel's key executives?

Roche Holdings AG Basel's management team includes the following people:
  • Dr. Severin Schwan, CEO & Exec. Director (Age 52)
  • Dr. Alan Hippe, Chief Financial & Information Officer (Age 52)
  • Dr. Gottlieb A. Keller, Gen. Counsel & Corp. Sec. (Age 65)
  • Ms. Cristina A. Wilbur, Head of Group HR (Age 52)
  • Dr. Karl Mahler, Head of Investor Relations

What is Roche Holdings AG Basel's stock symbol?

Roche Holdings AG Basel trades on the OTCMKTS under the ticker symbol "RHHBY."

Who are Roche Holdings AG Basel's major shareholders?

Roche Holdings AG Basel's stock is owned by a number of retail and institutional investors. Top institutional investors include Parametric Portfolio Associates LLC (0.08%), Schafer Cullen Capital Management Inc (0.02%), Douglass Winthrop Advisors LLC (0.01%), Riverbridge Partners LLC (0.01%), Ferguson Wellman Capital Management Inc. (0.01%) and Grimes & Company Inc. (0.00%).

Which institutional investors are selling Roche Holdings AG Basel stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Schafer Cullen Capital Management Inc, Kempner Capital Management Inc., Parametric Portfolio Associates LLC, Oxbow Advisors LLC, Scout Investments Inc., Fisher Asset Management LLC, Kornitzer Capital Management Inc. KS, and Taylor Cottrill Erickson & Associates Inc..

Which institutional investors are buying Roche Holdings AG Basel stock?

RHHBY stock was acquired by a variety of institutional investors in the last quarter, including Park National Corp OH, S&T Bank PA, Jolley Asset Management LLC, Douglass Winthrop Advisors LLC, Chartwell Investment Partners LLC, Hancock Whitney Corp, Anderson Hoagland & Co., and Ferguson Wellman Capital Management Inc..

How do I buy shares of Roche Holdings AG Basel?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Roche Holdings AG Basel's stock price today?

One share of RHHBY stock can currently be purchased for approximately $43.43.

How big of a company is Roche Holdings AG Basel?

Roche Holdings AG Basel has a market capitalization of $297.43 billion and generates $61.87 billion in revenue each year. The company earns $13.58 billion in net income (profit) each year or $2.54 on an earnings per share basis. Roche Holdings AG Basel employs 97,735 workers across the globe.

What is Roche Holdings AG Basel's official website?

The official website for Roche Holdings AG Basel is www.roche.com.

How can I contact Roche Holdings AG Basel?

Roche Holdings AG Basel's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.